Tag: pancreatic cancer
-

GSK Licenses HUTCHMED’s HMPL-A830 in a Deal Worth Up to $1.295 Billion
GSK licensed HUTCHMED’s preclinical HMPL-A830 for up to $1.295 billion, gaining ex-Greater China rights to a KRAS-EGFR antibody-targeted therapy conjugate designed to combine EGFR-guided delivery with intracellular KRAS inhibition.
-

Revolution Medicines Wins FDA Approval for Rasonque in Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma after Phase 3 RASolute 302 showed a major survival benefit over chemotherapy.